India, Feb. 18 -- Cumberland Pharmaceuticals Inc. (CPIX) and SciClone Pharmaceuticals (Holdings) Limited, on Tuesday announced that Vibativ or telavancin injection has received approval from China's National Medical Products Administration or NMPA.
This approval follows an agreement granting SciClone exclusive rights to register, promote, and distribute the antibiotic in China.
Vibativ is an FDA-approved, life-saving antibiotic used to treat hospital-acquired and ventilator-associated pneumonia and complicated skin and skin structure infections or cSSSI caused by Gram-positive bacteria, including multidrug-resistant strains like MRSA. The drug generated net revenue of $8.8 million in 2023.
The approval in China opens the door for Vibativ...